Status:
COMPLETED
Piperacillin/Tazobactam for Bacteremia With Organisms Producing Chromosomally-Encoded AmpC Beta-Lactamase
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Japan Health Sciences Foundation
Conditions:
Bacteremia
AmpC Beta-lactamase
Eligibility:
All Genders
18+ years
Brief Summary
Nosocomial bloodstream infections are important causes of morbidity and mortality caused by AmpC beta-lactamase-producing Enterobacteriaceae. The information collected will optimize the management of ...
Detailed Description
The following information will be collected: age, sex, occupation, hospital location at the time of positive culture (ER, medical ward, ICU etc), prior hospitalization, receipt of outpatient dialysis,...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Clinical information is collected by chart review of "case" and "control" patients. A "case" patient is defined as follows:
- One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii.
- The patient received piperacillin/tazobactam as the initial empiric therapy.
- The organism was susceptible to piperacillin/tazobactam.
- A "control" patient is defined as follows:
- One or more blood cultures are positive for E. cloacae, E. aerogenes, C. freundii, S. marcescens or M. morganii.
- The patient received a carbapenem or fluoroquinolone antimicrobial as the initial empiric therapy.
- The organism was susceptible to the empiric regimen.
Exclusion
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2017
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT00414193
Start Date
February 1 2007
End Date
December 1 2017
Last Update
June 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213